We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Astrazeneca Plc | LSE:AZN | London | Ordinary Share | GB0009895292 | ORD SHS $0.25 |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -256.00 | -2.14% | 11,708.00 | 11,710.00 | 11,716.00 | 11,908.00 | 11,678.00 | 11,844.00 | 2,989,208 | 16:35:08 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 54.07B | 7.04B | 4.5371 | 25.82 | 185.51B |
From Feb 2020 to Feb 2025
LONDON--AstraZeneca PLC (AZN.LN) said Monday that the phase 3 trial of treatment drug Lynparza has met its primary endpoint.
The pharmaceutical company said the trial showed a statistically-significant and clinically-meaningful improvement in progression-free survival for patients treated with Lynparza tablets, compared to chemotherapy.
Write to Tapan Panchal at tapan.panchal@wsj.com
(END) Dow Jones Newswires
June 05, 2017 02:32 ET (06:32 GMT)
Copyright (c) 2017 Dow Jones & Company, Inc.
1 Year Astrazeneca Chart |
1 Month Astrazeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
